Casopitant

Casopitant

Clinical data
ATC code	A04AD13 (WHO)
Identifiers
IUPAC name (2S,4S)-4-(4-Acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-1-piperidinecarboxamide
CAS Number	414910-27-3
PubChem CID	23725089
ChemSpider	25069049
UNII	3B03KPM27L
ChEMBL	ChEMBL2107320
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C30H35F7N4O2
Molar mass	616.26 g/mol
3D model (JSmol)	Interactive image
SMILES CC1=C(C=CC(=C1)F)[C@@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C
InChI InChI=1S/C30H35F7N4O2/c1-18-13-24(31)5-6-26(18)27-17-25(40-11-9-39(10-12-40)20(3)42)7-8-41(27)28(43)38(4)19(2)21-14-22(29(32,33)34)16-23(15-21)30(35,36)37/h5-6,13-16,19,25,27H,7-12,17H2,1-4H3/t19-,25-,27+/m1/s1 Key:XGGTZCKQRWXCHW-JRLVAEJTSA-N
(verify)

WikiDoc Resources for Casopitant
Articles
Most recent articles on Casopitant Most cited articles on Casopitant Review articles on Casopitant Articles on Casopitant in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Casopitant Images of Casopitant Photos of Casopitant Podcasts & MP3s on Casopitant Videos on Casopitant
Evidence Based Medicine
Cochrane Collaboration on Casopitant Bandolier on Casopitant TRIP on Casopitant
Clinical Trials
Ongoing Trials on Casopitant at Clinical Trials.gov Trial results on Casopitant Clinical Trials on Casopitant at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Casopitant NICE Guidance on Casopitant NHS PRODIGY Guidance FDA on Casopitant CDC on Casopitant
Books
Books on Casopitant
News
Casopitant in the news Be alerted to news on Casopitant News trends on Casopitant
Commentary
Blogs on Casopitant
Definitions
Definitions of Casopitant
Patient Resources / Community
Patient resources on Casopitant Discussion groups on Casopitant Patient Handouts on Casopitant Directions to Hospitals Treating Casopitant Risk calculators and risk factors for Casopitant
Healthcare Provider Resources
Symptoms of Casopitant Causes & Risk Factors for Casopitant Diagnostic studies for Casopitant Treatment of Casopitant
Continuing Medical Education (CME)
CME Programs on Casopitant
International
Casopitant en Espanol Casopitant en Francais
Business
Casopitant in the Marketplace Patents on Casopitant
Experimental / Informatics
List of terms related to Casopitant

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Casopitant (trade names Rezonic (US), Zunrisa (EU)) is an neurokinin 1 (NK₁) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV). It is currently under development by GlaxoSmithKline (GSK).

In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.

See also

• Aprepitant
• Fosaprepitant
• Maropitant